Study of sirolimus and octreotide for advanced neuroendocrine tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor is a type called G1 or G2 neuroendocrine tumor, located in the stomach, intestines, or pancreas, and has spread or cannot be surgically removed.
- Your tumor is not causing symptoms from excess hormones (non-functional).
- You have risk factors that suggest the tumor may grow more quickly (poor prognostic factors).
- You are in good enough health to perform daily activities (ECOG score 0 to 2) and your organ function is adequate.
- You have not received certain prior treatments, such as somatostatin analogs or mTOR inhibitors, unless it's been over 6 months since finishing those treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial studies whether it’s helpful to keep taking somatostatin “analog” injections even after your neuroendocrine tumor has started growing despite the usual dose. It also looks at how the next treatment choice (targeted pills or PRRT) fits in for people with non-functional, well-differentiated GEP NET.
This trial looks at how well octreotide microspheres work for people with neuroendocrine tumors that cannot be removed by surgery or have spread to other parts of the body. It aims to help doctors understand the real-world benefits of this treatment.
Hear when a new Gastroenteropancreatic Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.